Opioid manufacturers and distributors agreed to pay approximately $50 billion to U.S. states and the District of Columbia between 2022 and the late 2030s, with eighty-five per cent required to fund direct opioid remediation.
Opioid manufacturers and distributors agreed to pay approximately $50 billion to U.S. states, with 85% required to fund direct opioid remediation.
552c7ae14Topic
FDA ibogaine clinical trials
First government-funded clinical trials of ibogaine for opioid addiction and PTSD, conducted by the FDA and VA.
13 claims·1 news story